

**Priority question for written answer P-000524/2021/rev.1
to the Commission**
Rule 138
Lukas Mandl (PPE)

Subject: Surplus COVID-19 vaccination doses for developing countries

The European Union and its Member States have committed EUR 850 million to the COVAX initiative (EUR 100 million as an EU grant, 400 million as a European Investment Bank loan and 350 million through contributions by Member States) in order to support millions of people in Africa, Asia, the Caribbean and the Pacific, as well as in Europe's eastern and southern neighbourhood, with vaccines against the COVID-19 virus.

So far, the European Union has secured up to 2 265 million doses (with potentially another 260 million doses) through Advance Purchase Agreements for its own population of 447.7 million people. When putting these figures into context and taking into account the fact that each vaccination consists of two doses, the EU has ordered over 2½ times the number of vaccines necessary to protect each and every EU citizen.

1. Once the EU population has been vaccinated, what are the plans for the surplus vaccination doses?
2. Will the surplus vaccination doses be sold at market prices to other countries?
3. Is the Commission considering donating the surplus vaccination doses to developing countries, as a form of in-kind official development assistance?